Viking Therapeutics' Swing Trade Potential Emerges - Competition/Dilution Risks Remain [Seeking Alpha]
Viking Therapeutics, Inc. (VKTX)
Last viking therapeutics, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vikingtherapeutics.com
Company Research
Source: Seeking Alpha
The management has also prudently focused on the oral/subcutaneous VK2735 clinical trials, potentially stretching their balance sheet over the next two years of unprofitability before requiring any capital raises. Execution risks persist, due to VKTX's Phase 3 trial completion no earlier than 2027 and commercialization sometime in 2028, along with future dilution risks from negative cash flows. This is worsened by the heightened competition from NVO's recent US FDA approval for oral Wegovy along with PFE MET-097i's high double digits weight loss rate and reduced dosing frequency. VKTX is best suited for patient investors or traders seeking swing trade opportunities, with technical support at $33 and resistance at $39/$40, pending future breakouts. Pla2na/iStock via Getty Images I previously covered Viking Therapeutics, Inc. VKTX ) in July 2025, discussing its promising path to GLP-1 monetization, attributed to the excellent obesity/diabetes candidates and the ongoing Phase
Show less
Read more
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VKTX alerts
High impacting Viking Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VKTX
News
- Viking Therapeutics (VKTX) Is Up 8.9% After Rival Data Bolsters Its Oral Obesity Program [Yahoo! Finance]Yahoo! Finance
- Here is Why H.C. Wainwright Sees Immense Upside for Viking Therapeutics (VKTX) [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics, Inc. (VKTX): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics (VKTX): Rethinking Valuation After a Sharp Pullback and Strong Multi-Year Run [Yahoo! Finance]Yahoo! Finance
- 1 Bold Prediction for Viking Therapeutics in 2026 [Yahoo! Finance]Yahoo! Finance
VKTX
Earnings
- 10/22/25 - Miss
VKTX
Sec Filings
- 11/5/25 - Form SCHEDULE
- 10/28/25 - Form 4
- 10/28/25 - Form 4
- VKTX's page on the SEC website